In an 80-year-old man with influenza A (H1N1) pneumonia who is hypoxemic requiring 4 L/min oxygen to maintain SpO₂ of 90%, what is the appropriate dose and duration of oseltamivir, is baloxavir indicated, should empiric antibiotics be started, and what radiographic features distinguish viral from bacterial pneumonia on chest X‑ray?

Management of severe influenza A (H1N1) pneumonia in an 80-year-old

• Oseltamivir 75 mg PO twice daily for 5 days is indicated now; adjust for renal impairment if CrCl ≤60 mL/min, and do not use “high-dose” or extended duration routinely. 1, 2
• Start standard empiric antibacterial therapy for community-acquired pneumonia (CAP) concurrently. 1
• Baloxavir has no role in severe, hospitalized influenza pneumonia. 3
• Viral pneumonias typically show bilateral, patchy, interstitial or perihilar reticulonodular opacities; lobar consolidation favors bacterial coinfection (but CXR alone cannot reliably distinguish). 1

Antiviral therapy (mortality, morbidity, QoL focus)

• Give oseltamivir now: 75 mg PO BID for 5 days. If moderate renal impairment (CrCl >30–60): 30 mg BID; severe (CrCl >10–30): 30 mg once daily; hemodialysis: 30 mg after each HD session (max 5 days). Avoid in ESRD not on dialysis. Do not up-dose. 2

  • Rationale: ATS/IDSA CAP guideline strongly recommends antivirals for influenza-positive CAP in inpatients to reduce mortality; benefit persists even if >48 h from symptom onset. High-dose offers no added outcome benefit. 1, 4, 5, 6

• Baloxavir: Not recommended in severe disease; WHO 2024 updates conditionally favor oseltamivir for severe cases and restrict baloxavir to high‑risk, non‑severe within 48 h. Resistance concerns exist. 3, 7, 8

Empiric antibacterial therapy (because coinfection increases mortality)

• Start standard CAP antibiotics simultaneously. 1
  • Typical inpatient non-severe CAP options (adapt per local antibiogram/allergies):
    • Beta-lactam (e.g., ceftriaxone, cefotaxime, or ampicillin-sulbactam) plus a macrolide; or a respiratory fluoroquinolone monotherapy.
  • Add MRSA coverage (e.g., vancomycin or linezolid) if risk factors or severe, rapidly progressive disease, hemoptysis, cavitation, or post-influenza necrotizing pattern. De-escalate when cultures negative and patient improves. 1
  • Duration: usually 5–7 days for CAP; extend to 10–21 days if MRSA or gram-negative bacilli suspected/confirmed. 9, 1

Imaging: viral vs bacterial pneumonia on chest X-ray

• Viral influenza pneumonia:
  • Bilateral, diffuse or patchy interstitial/perihilar opacities; reticulonodular pattern; ground-glass appearance; lower-lobe or peribronchial thickening.
• Bacterial coinfection:
  • Focal lobar/alveolar consolidation, cavitation, or pleural effusion more suggestive.
• Caveat: CXR patterns overlap; do not rely on CXR alone to exclude bacterial coinfection—hence empiric antibiotics. 1

Practical algorithm (bedside)

• Immediately:
  • Oseltamivir 75 mg BID x 5 days (renal-adjust as above). 2
  • Start empiric CAP antibiotics; add MRSA coverage if risk factors. 1
  • Obtain blood cultures, sputum (or tracheal) cultures, nasal MRSA screen; check renal function for dosing.
• Do NOT use baloxavir in this severe/hypoxemic inpatient. 3
• Reassess at 48–72 h; narrow/stop antibiotics if bacterial infection excluded and patient clinically improves. 1

Pitfalls to avoid

• Delaying antivirals pending test timing or symptom duration >48 h—start now. 1
• Using high-dose or extended oseltamivir without indication—no outcome benefit. 4, 5
• Skipping empiric antibiotics in influenza pneumonia—coinfection is common and deadly. 1
• Over-relying on procalcitonin/CXR alone to rule out bacterial coinfection—can be falsely low/indeterminate in viral–bacterial coinfection. 1